Uploaded January 2026 | Updated September 2026, 2 weeks ago
Drug discovery has a persistent bottleneck: predicting how a potential drug binds to its target can take years of lab work.
SandboxAQ CEO Jack Hidary joins Fox Business’ Maria Bartiromo to discuss AQAffinity, a new open-source model built with a consortium that includes Bristol Myers Squibb and Bayer to help accelerate research for cancer, Alzheimer’s, diabetes, and more. The conversation also turns to the global AI race with China, the urgency of preparing for quantum-enabled cyberattacks, and why post-quantum cryptography is becoming a must-have for financial systems and crypto. Plus, Hidary shares his outlook on humanoid robots in the workplace, and why he sees automation as a major driver of what comes next.
Learn more about SandboxAQ here: sandboxaq.com
#sandboxaq
Drug discovery has a persistent bottleneck: predicting how a potential drug binds to its target can take years of lab work.
SandboxAQ CEO Jack Hidary joins Fox Business’ Maria Bartiromo to discuss AQAffinity, a new open-source model built with a consortium that includes Bristol Myers Squibb and Bayer to help accelerate research for cancer, Alzheimer’s, diabetes, and more. The conversation also turns to the global AI race with China, the urgency of preparing for quantum-enabled cyberattacks, and why post-quantum cryptography is becoming a must-have for financial systems and crypto. Plus, Hidary shares his outlook on humanoid robots in the workplace, and why he sees automation as a major driver of what comes next.
Learn more about SandboxAQ here: sandboxaq.com
#sandboxaq
